The novel HBx mutation F30V correlates with hepatocellular carcinoma in vivo, reduces hepatitis B virus replicative efficiency and enhances anti-apoptotic activity of HBx N terminus in vitro
| Autor: | Francesca Ceccherini-Silberstein, Rossana Scutari, Massimo Andreoni, Mario Angelico, Carmen Mirabelli, Massimo Levrero, Laura Belloni, Maria Francesca Cortese, Loredana Sarmati, Gabriele Missale, Caterina Pasquazzi, Valentina Svicher, J. Vecchiet, Simona Francioso, G.A. Palumbo, Matteo Surdo, A. Sacco, Hervé Fleury, Pascale Trimoulet, Carlo Federico Perno, L. Carioti, Mohammad Alkhatib, Alberto Spanò, Giuseppina Cappiello, Romina Salpini |
|---|---|
| Rok vydání: | 2018 |
| Předmět: |
0301 basic medicine
Microbiology (medical) Adult Male apoptosis hbx hepatitis b hepatitis b virus replication hepatocellular carcinoma Hepatitis B virus Carcinoma Hepatocellular Genotype 030106 microbiology Apoptosis Biology medicine.disease_cause Virus Replication 03 medical and health sciences 0302 clinical medicine Hepatitis B Chronic medicine Humans Viral Regulatory and Accessory Proteins 030212 general & internal medicine Aged Mutation Liver Neoplasms General Medicine cccDNA Hep G2 Cells Hepatitis B Middle Aged Settore MED/07 - Microbiologia e Microbiologia Clinica medicine.disease digestive system diseases HBx Infectious Diseases Liver Structural Homology Protein Hepatocellular carcinoma DNA Viral Cancer research Trans-Activators Female |
| Zdroj: | Clinical microbiology and infection : the official publication of the European Society of Clinical Microbiology and Infectious Diseases. 25(7) |
| ISSN: | 1469-0691 |
| Popis: | We aimed to investigate HBx genetic elements correlated with hepatitis B virus (HBV) -related hepatocellular carcinoma (HCC) and their impact on (a) HBV replicative efficiency, (b) HBx binding to circular covalently closed DNA (cccDNA), (c) apoptosis and cell-cycle progression, and (d) HBx structural stability.This study included 123 individuals chronically infected with HBV: 27 with HCC (77.9% (21/27) genotype D; 22.1% (6/27) genotype A) and 96 without HCC (75% (72/96) genotype D; 25.0% (24/96) genotype A). HepG2 cells were transfected by wild-type or mutated linear HBV genome to assess pre-genomic RNA (pgRNA) and core-associated HBV-DNA levels, HBx-binding onto cccDNA by chromatin immunoprecipitation-based quantitative assay, and rate of apoptosis and cell-cycle progression by cytofluorimetry.F30V was the only HBx mutation correlated with HCC (18.5% (5/27) in HCC patients versus 1.0% (1/96) in non-HCC patients, p 0.002); a result confirmed by multivariate analysis. In vitro, F30V determined a 40% and 60% reduction in pgRNA and core-associated HBV-DNA compared with wild-type (p0.05), in parallel with a significant decrease of HBx binding to cccDNA and decreased HBx stability. F30V also decreased the percentage of apoptotic cells compared with wild-type (14.8 ± 6.8% versus 19.1 ± 10.1%, p0.01, without affecting cell-cycle progression) and increased the probability of HBx-Ser-31 being phosphorylated by PI3K-Akt kinase (known to promote anti-apoptotic activity).F30V was closely correlated with HBV-induced HCC in vivo, reduced HBV replicative efficiency by affecting HBx-binding to cccDNA and increased anti-apoptotic HBx activity in vitro. This suggests that F30V (although hampering HBV's replicative capacity) may promote hepatocyte survival, so potentially allowing persistent production of viral progeny and initiating HBV-driven hepatocarcinogenesis. Investigation of viral genetic markers associated with HCC is crucial to identify those patients at higher risk of HCC, who hence deserve intensive liver monitoring and/or early anti-HBV therapy. |
| Databáze: | OpenAIRE |
| Externí odkaz: |
|